Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

Constructive Bio is a biotechnology company focused on genome rewriting to advance bioprocesses and biopharmaceuticals. By transforming living cells into biofactories, it aims to develop sustainable materials and therapeutics. The company possesses the capability to create virus-resistant organisms and utilizes its proprietary technology to biosynthesize various classes of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram the genetic code, enabling the production of natural molecules and exploring chemical spaces that are not accessible through traditional biological methods. Constructive Bio's work positions it at the forefront of biotechnology, paving the way for the next generation of sustainable solutions in the life sciences sector.

LinkGevity is a biotechnology company specializing in drug discovery, with a focus on longevity and age-related diseases. It operates an AI-powered platform designed to expedite the development of life-saving medications. By combining AI and pharmaceutical expertise, the company analyzes extensive datasets to predict and identify promising drug candidates, aiming to extend healthy lifespan and bring innovative treatments to market more swiftly.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

New Wave Biotech is a company that specializes in developing software aimed at optimizing downstream processes for alternative protein and synthetic biology products. By leveraging computational modeling and artificial intelligence, the company’s platform conducts virtual experiments on a vast array of potential production processes. This allows it to analyze experimental data and provide actionable recommendations for enhancing yield, cost efficiency, quality, and sustainability. As a result, New Wave Biotech enables biomanufacturers to accelerate their research and development efforts and reduce production costs, facilitating a quicker and more efficient pathway for bringing innovative products to market.

New Wave Biotech is a company that specializes in developing software aimed at optimizing downstream processes for alternative protein and synthetic biology products. By leveraging computational modeling and artificial intelligence, the company’s platform conducts virtual experiments on a vast array of potential production processes. This allows it to analyze experimental data and provide actionable recommendations for enhancing yield, cost efficiency, quality, and sustainability. As a result, New Wave Biotech enables biomanufacturers to accelerate their research and development efforts and reduce production costs, facilitating a quicker and more efficient pathway for bringing innovative products to market.

Dia Beta Labs is a biotechnology company dedicated to improving the lives of individuals with metabolic diseases. It operates from Ulster, where it has access to advanced facilities and a network of experts. The company's focus is on developing therapeutic agents to address the decline of pancreatic health in patients, with the goal of achieving more sustainable and effective weight loss than current options. Its discovery platform uses industry-standard methodologies and models to identify and advance lead molecules for animal research.

Keltic Pharma Therapeutics enhances drug discovery through innovative scientific research, resulting in a healthier future.

ChromaTwist is a developer of innovative ultraviolet fluorescent dyes designed for applications in bio-sensing and bio-imaging diagnostic tests. The company's proprietary technology platform utilizes shifted organic fluorescent dyes, which emit visible light upon UV irradiation. These dyes are composed of aromatic organic materials featuring donor and acceptor groups, allowing them to absorb UV light and emit across the full visible spectrum. ChromaTwist's modular and scalable chemistry enables the continuous advancement of their fluorophores, thereby expanding their potential applications in the healthcare sector, particularly in areas like flow cytometry and multiphoton microscopy.

BindEthics is a business specializing in the production and supply of eco-friendly adhesives. Their primary product is a sustainable, non-toxic glue that is not derived from fossil fuels. This innovative adhesive is designed to replace traditional, petroleum-based adhesives, particularly in the manufacturing of engineered wood products like furniture. By offering a bio-based alternative, BindEthics enables its customers to produce non-toxic, sustainable, and recyclable products, thereby promoting a more environmentally responsible approach to manufacturing.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Lentitek is a cell and gene therapy company focused on developing innovative treatments for cancer patients. The company is dedicated to making advanced therapeutics more accessible by enhancing the production of lentiviral vectors, which are essential for gene therapies. Lentitek employs a proprietary method that utilizes a novel promoter and a triple transfection production process to significantly increase viral yields by tenfold or more. This approach not only improves the efficiency of lentiviral production but also aims to lower production costs for healthcare providers, thereby broadening the availability of its therapies to a larger patient population.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, that focuses on developing innovative treatments for patients with autoimmune diseases and cancers. Founded in 2009, the company is dedicated to creating first-in-class antibody therapies, particularly its lead product, annexuzlimab, a monoclonal antibody designed to target and inhibit annexin-A1. This approach aims to modulate both the innate and adaptive immune systems, thereby enhancing treatment options for healthcare providers and improving patient outcomes. Through its specialized research and development efforts, MedAnnex seeks to address significant unmet medical needs in the field of immunotherapy.

ThirtyFiveBio is a biotechnology company focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, an area marked by significant unmet clinical needs. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify contemporary small-molecule modulators of specific proteins, particularly targeting GPR35 signaling pathways. By addressing the challenges associated with digestive system malignancies, ThirtyFiveBio aims to offer therapeutic solutions that could help prevent tumor growth and improve patient outcomes.

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

AgriSound is an agri-tech company that specializes in advanced sound analysis to monitor insect activity, particularly focusing on pollinators. The company has developed a pollination management platform that utilizes sound, environmental, and visual technology sensors to record and analyze insect behavior in near real-time. This innovative approach allows beekeepers, farmers, and researchers to remotely manage beehives and gain insights into hive status and pollination dynamics. By employing predictive algorithms, AgriSound's platform helps identify subtle changes that may impact pollination, enabling users to make informed decisions and take appropriate actions to maintain optimal pollination conditions. Ultimately, AgriSound aims to enhance agricultural operations while promoting biodiversity.

Fuse Diagnostics is a company dedicated to providing lab-quality diagnostic information through innovative and cost-effective testing solutions. The company manufactures diagnostic products designed to deliver accurate results for various applications, including food and water testing, bioprocessing industry needs, and cell biology research. Fuse Diagnostics aims to make high-quality diagnostic information accessible wherever it is needed, offering low-cost test kits with integrated readout technology that provide rapid results.

LIfT BioSciences is a biotechnology company based in London, established in 2016, that specializes in advanced innate immuno-cell therapies. It has developed a unique platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), which enables the production of Immunomodulatory Alpha Neutrophils (IMANs) from induced pluripotent stem cells (iPSCs). This technology aims to address the limitations of existing therapies for solid tumors by utilizing CAR neutrophil cell therapy. The IMANs can alter the tumor microenvironment, enhancing the immune response and enabling a more effective attack on tumors. By leveraging proprietary enhancement media and genetic engineering, LIfT BioSciences seeks to significantly increase the cancer-fighting capabilities of these cells, offering patients the potential for improved outcomes and lasting immunity against cancer.

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to reduce variability in patient populations and identify individuals with similar underlying neurobiology. This targeted approach aims to enhance the research and development of neuroscience drugs in areas with significant unmet medical needs, ultimately advancing treatment options for these complex conditions.

BSF Enterprise is focused on advancing biotechnology solutions through an acquisition-led growth strategy. The company specializes in the development of lab-grown tissues, leveraging cell-based tissue engineering to produce cultured meat, lab-grown leather, human corneas, collagen, and skin substitutes. By integrating innovative technologies, BSF Enterprise aims to transform sustainable practices across various sectors. Additionally, the company seeks investment opportunities in the biotechnology, marketing, and e-commerce sectors in the United Kingdom, positioning itself as a key player in the evolving landscape of biotech solutions.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

SökerData is a biotechnology company that specializes in research and data analysis solutions focused on disease-related datasets. The company has developed a data visualization platform designed to analyze biomarkers in clinical outcomes across various demographics. This platform provides researchers with essential features and tools for interpreting large datasets, facilitating early drug discovery. By enabling researchers to better understand the impact of biomarkers on different populations, SökerData supports informed decision-making and enhances the comprehension of disease outcomes in diverse demographic groups.

Aelius Biotech specializes in developing advanced models of the mucosal surfaces of the human body, including the gastrointestinal tract and airways. The company is actively working on creating model systems for the eye and cervico-vaginal tract. Aelius Biotech provides a comprehensive range of in vitro and in vivo testing services, including simple lab assays, routine testing, and rheology. Their integrated model gut system allows healthcare industry participants to simulate key processes such as digestion, mucus permeation, and epithelial absorption in one cohesive platform. By conducting human trials and offering detailed insights, Aelius Biotech aids healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

AMPLY Discovery is a biotechnology company focused on drug discovery, utilizing machine learning and synthetic biology to explore vast biological datasets for novel drug and nutraceutical candidates. The company operates a proprietary platform that integrates in silico and in vitro approaches to identify first-in-class molecules, addressing significant health challenges such as cancer, metabolic diseases, and multidrug-resistant infections. By digitizing life's natural diversity, AMPLY enhances the predictability and cost-effectiveness of discovering new therapeutics, enabling research entities to identify promising drug candidates based on their functional properties.

Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Cellcraft is a B2B cultivated meat start-up based in Cambridge, focused on developing a scalable manufacturing platform for cultivated meat. The company provides a comprehensive system that includes raw materials, hardware, software, and bioprocesses, enabling food producers to locally manufacture delicious cultivated meats at a commercial scale. By utilizing intelligent technologies and AI-driven software, Cellcraft aims to empower food producers to create customized meat products that cater to local tastes and specifications. The company addresses significant global challenges related to food security and sustainability, promoting access to sustainable food solutions.

Clean Food Group specializes in the development of sustainable food ingredients, focusing on providing eco-friendly alternatives to traditional fats and oils. The company produces a range of products, including liquid oils such as soybean oil and solid fats like palm oil, cocoa butter, and milk fat. Utilizing a proprietary cellular agriculture system, Clean Food Group commercializes palm oil production through fermentation using natural yeast in a sustainable, non-GM process. This innovative approach offers customers a local and circular alternative to conventional palm oil, addressing both environmental concerns and health considerations while maintaining quality and taste.

CellRev is a biotechnology company that specializes in advancing cell manufacturing processes through innovative bioprocessing technology. The company focuses on enabling the transition from traditional batch processing to continuous processing for adherent cells, which enhances yield and reduces both operating costs and capital expenditure. By addressing critical challenges such as aggregation, clumping, and cell detachment, CellRev offers unique solutions for developers in the fields of cultured meat, cell therapy, and biologics. Its proprietary cell detachment process, combined with a specially designed bioprocess, positions CellRev as a leader in improving the efficiency of manufacturing processes for cell-based vaccines, therapies, and drugs. This disruptive approach aims to eliminate the need for serum in production, thereby streamlining operations for clients in the biomanufacturing landscape.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

PES Technologies specializes in innovative agricultural technology, specifically focusing on soil health analysis. The company has developed a microbe sensor that monitors the biological properties of soil by analyzing microbe health. This technology provides valuable insights into the long-term changes in soil quality, enabling farmers and agronomists to make informed soil management decisions swiftly. By offering a tool to assess soil conditions effectively, PES Technologies contributes to enhancing farming practices and promoting sustainable agriculture.

PES Technologies specializes in innovative agricultural technology, specifically focusing on soil health analysis. The company has developed a microbe sensor that monitors the biological properties of soil by analyzing microbe health. This technology provides valuable insights into the long-term changes in soil quality, enabling farmers and agronomists to make informed soil management decisions swiftly. By offering a tool to assess soil conditions effectively, PES Technologies contributes to enhancing farming practices and promoting sustainable agriculture.

Laverock Therapeutics is focused on advancing a gene silencing platform that facilitates the development of programmable, allogeneic cell therapies. This innovative platform allows for the engineering of next-generation cell therapies that are both adaptive and capable of responding to various intra- and extra-cellular environmental cues. By enhancing the functionality of these therapies, Laverock Therapeutics aims to improve the efficacy, safety, and accessibility of iPSC-derived products, addressing significant limitations associated with current therapeutic approaches. The company's work is positioned to benefit medical and biotechnology institutions seeking to leverage advanced cell therapy solutions.

Beta Bugs is an insect genetics company specializing in the development and distribution of high-performance Black Soldier Fly breeds aimed at enhancing productivity in the insect protein sector. The company operates a breeding program called HiPer-Fly® and maintains a dedicated egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By focusing on biotechnology and breeding techniques, Beta Bugs aims to create a sustainable protein source that can effectively replace traditional feed ingredients such as fishmeal and soymeal in livestock, aquaculture, and pet feed. Headquartered at the Easter Bush Campus, a recognized center for animal genetics, Beta Bugs collaborates closely with the Roslin Institute, noted for its pioneering work in animal genetics.

The Good Pulse is a producer of functional proteins and ingredients derived from pulses, specializing in plant-based foods and supplements. The company focuses on creating meat alternatives and cheese substitutes using precision fermentation techniques. By maximizing the functionality and nutritional value of pulse seeds, such as peas and soy, The Good Pulse aims to provide consumers with sustainable and ethical food options. Their products are designed to ensure that consumers do not have to compromise on taste or experience while adopting a more efficient diet. Through its innovative approach, The Good Pulse is dedicated to revalorizing all components extracted from pulses, contributing to a more sustainable food system.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

Carbogenics Ltd is a company based in Edinburgh, United Kingdom, that specializes in developing sustainable solutions for agriculture and waste management. Founded in 2016, Carbogenics focuses on converting disposable coffee cups and other non-recyclable paper-based waste into plant fertilizer through an innovative low-carbon process. The company produces CreChar, a carbon additive that enhances biogas production and promotes plant growth, ultimately benefiting farmers by improving crop yields and profitability. In addition to its product offerings, Carbogenics provides consultancy and analytical services tailored for anaerobic digestion plant operators, addressing customer inquiries via phone, email, and online applications.

ThirtyFiveBio is a biotechnology company focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, an area marked by significant unmet clinical needs. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify contemporary small-molecule modulators of specific proteins, particularly targeting GPR35 signaling pathways. By addressing the challenges associated with digestive system malignancies, ThirtyFiveBio aims to offer therapeutic solutions that could help prevent tumor growth and improve patient outcomes.

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

AstronauTx is a biotechnology company focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative conditions. The company specializes in restoring the normal function of astrocytes, which are crucial for supporting neuronal activity and maintaining brain health. In healthy individuals, astrocytes play a vital role in metabolism and the integrity of the blood-brain barrier; however, in neurodegenerative diseases, their dysfunction can contribute to neurotoxicity. By targeting these processes, AstronauTx aims to enable healthcare professionals to more effectively address the challenges posed by dementias, ultimately improving patient outcomes.

TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.

Intellegens is a company that specializes in applying machine learning to enhance innovation across various industries, including materials, chemicals, and manufacturing. Its flagship product, Alchemite™, was initially developed at the University of Cambridge and is designed to train deep neural networks using sparse and noisy data, where conventional machine learning methods often struggle. This platform allows scientists, engineers, and analysts to optimize formulations, products, and processes while significantly reducing the number of experiments required, often by up to 90%. Alchemite™ features a user-friendly web interface and powerful graphical analysis tools, and it can be seamlessly integrated into existing data science workflows. The technology has been successfully applied in multiple fields, including drug discovery, materials development, and additive manufacturing, thereby enabling clients to extract greater value from their data and accelerate their development timelines.

ZiO Health is a biotechnology company focused on enhancing patient outcomes through its innovative pocket-sized laboratory testing technology. The company has developed proprietary biosensor devices that utilize machine learning algorithms to provide real-time results tailored to individual patient profiles. These multi-functional electronic devices are designed for measuring, testing, and detecting the molecular composition of various chemical and biological substances, enabling users to assess the presence, absence, or quantity of specific target molecules. By delivering quality home diagnostics and personalized testing solutions, ZiO Health aims to empower individuals to optimize their health and prevent illness.

Plasticell is a biotechnology company focused on developing innovative therapeutic solutions through advanced cell culture and drug discovery platforms. By investigating the biochemical mechanisms that govern stem cell behavior, Plasticell aims to create regenerative small molecule drugs that support tissue development and repair. The company offers comprehensive support for researchers in cell biology by enabling the testing of numerous cell culture variables, thereby optimizing laboratory protocols for various outcomes. This approach facilitates the differentiation of cells and enhances processes such as gene transduction and protein production, ultimately contributing to the advancement of novel therapies in regenerative medicine.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

Metalchemy is a pioneering technology company focused on developing and commercializing green nanotechnology solutions. It operates by transforming organic waste into valuable nanomaterials through its proprietary bio-nanotechnology processes. This innovative approach enables Metalchemy to produce eco-friendly bioplastics, contributing to reduced food waste and mitigating climate change impacts. The company's mission is to make green nanotechnology widely accessible, fostering a healthier and more sustainable future for all.

NK:IO is a biotechnology company focused on advancing innovative strategies for natural killer cell-mediated immunotherapy. It specializes in the development of both cell therapies and small molecule therapeutics, with a primary emphasis on cancer treatment. By harnessing the capabilities of natural killer cells, NK:IO aims to enhance the effectiveness of cancer therapies, providing physicians with improved tools to combat the disease. The company's commitment to research and development positions it at the forefront of immunotherapy advancements in the oncology field.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Corryn Biotechnologies is a biotechnology company focused on innovative solutions for chronic wound care. The company has developed the Heals device, which utilizes a contactless approach to enhance the dressing of chronic and complex wounds. Corryn's technology employs applicators that use voltages to extrude fine fibers from various fluids, allowing for the creation of advanced wound dressings. These dressings can be made from both synthetic and natural materials, with the option to include active ingredients. This method enables the deposition of non-woven meshes, contributing to effective tissue repair and improving patient outcomes in wound management.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

SMi Systems is a biomedical research and medical equipment manufacturing organization that specializes in developing advanced discovery and diagnostic tools. Its flagship product, SMi Drug Discovery, is a high-performance diagnostic device capable of detecting diseases within the first 24 hours of infection. This innovative device can simultaneously identify multiple diseases and process numerous patient samples in a matter of minutes. By facilitating the detection of individual disease-associated molecules, SMi Systems' automated and high-throughput diagnostic tools enable scientists to measure critical molecular interactions essential for understanding therapeutic mechanisms. This capability allows researchers to observe a vast diversity of molecular interactions across various disease areas and monitor drug binding to their targets, thereby advancing scientific research and clinical diagnostics.

SMi Systems is a biomedical research and medical equipment manufacturing organization that specializes in developing advanced discovery and diagnostic tools. Its flagship product, SMi Drug Discovery, is a high-performance diagnostic device capable of detecting diseases within the first 24 hours of infection. This innovative device can simultaneously identify multiple diseases and process numerous patient samples in a matter of minutes. By facilitating the detection of individual disease-associated molecules, SMi Systems' automated and high-throughput diagnostic tools enable scientists to measure critical molecular interactions essential for understanding therapeutic mechanisms. This capability allows researchers to observe a vast diversity of molecular interactions across various disease areas and monitor drug binding to their targets, thereby advancing scientific research and clinical diagnostics.

PfBIO is a biotechnology company that discovers and develops natural, bacteria-based products to enhance plant health and protect crops from diseases, providing sustainable alternatives to synthetic agrochemicals. The company's innovative platform involves sourcing bacteria from the environment and selecting those with the ability to combat plant pathogens, improve crop yields, and enrich soil quality.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

Autolomous Ltd is a technology company founded in 2019 and based in Mayfair, United Kingdom, that specializes in developing software solutions for cell and gene therapy manufacturers. Its flagship platform, autoloMATE®, is a cloud-native system that offers comprehensive, end-to-end solutions for advanced therapy manufacturing. The platform facilitates the scheduling of patient cell collections, transportation logistics, and tracking of the manufacturing process to ensure compliance with regulatory requirements. Additionally, autoloMATE® supports the management of electronic batch records, provides insights reporting, and oversees review and release activities. The software is designed to be highly configurable, allowing clients to customize workflows to suit their needs. Autolomous emphasizes compliance with regulatory standards and has achieved multiple ISO certifications in areas such as information security, quality management, and environmental management. By leveraging advanced technology and secure data management practices, Autolomous aims to enhance the availability and affordability of autologous medicines for patients.

Orthonika Limited, founded in 2014 and based in London, United Kingdom, specializes in the development of anatomical meniscus replacement devices, specifically the MenisciKnit. This innovative product addresses the significant clinical gap in treating meniscus injuries, which can lead to debilitating conditions such as osteoarthritis. Traditional treatment methods, including partial meniscectomy and allograft transplantation, have notable limitations, such as incomplete restoration of knee biomechanics and issues related to donor availability and infection risk. Orthonika's MenisciKnit utilizes a unique fiber-reinforced structure embedded in a proprietary polymer, effectively mimicking the natural tissue's properties. This advanced approach aims to restore knee function, helping patients with severe meniscus injuries return to an active lifestyle while fulfilling a critical unmet need in orthopedic care.

Hexis Lab is a biotechnology company specializing in the research and development of innovative skincare products tailored for diverse skin types. The company focuses on creating ethically targeted solutions aimed at protecting and repairing sun-damaged skin while enhancing overall well-being. Utilizing a discovery platform that incorporates big data cloud computing and in-silico computer modeling, Hexis Lab screens an extensive database of naturally derived plant compounds for their efficacy against specific cellular targets. By leveraging proprietary AI techniques, the company accelerates product research, identifies novel ingredients, and formulates effective products for the beauty, skincare, personal care, nutraceuticals, and pharmaceutical sectors.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Maxion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for diseases driven by ion channels and G protein-coupled receptors (GPCRs). The company utilizes a unique drug discovery platform that integrates ion channel-modulating mini-proteins, known as knottins, derived from venom and other natural sources. By combining these knottins with antibody frameworks, Maxion aims to create long-acting, safe, and effective therapeutics that address previously inaccessible medical targets. This approach enables the potential treatment of various conditions, including chronic pain, autoimmune disorders, and heart disease, ultimately enhancing patient care through advanced drug development.

Flybox® is an Insect Waste Management (IWM) company delivering innovative insect bioconversion technology and expert support to revolutionise waste management. Flybox® provides tailored IWM solutions for established waste and food businesses, alongside a streamlined breeding and monetisation service that simplifies startup and scaling for new operators. Its modular IWM systems integrate seamlessly with existing waste infrastructure, allowing businesses to transform organic waste streams and byproducts into valuable proteins and fertilisers. With patented technology and a steadfast commitment to circular economy principles, Flybox® is advancing global efforts to reduce landfill dependency, minimise reliance on deforestation-linked soy, and enhance food security. Headquartered in the UK and active internationally, Flybox® is a leader in sustainable waste solutions, driving positive change across agriculture, waste management, and environmental resilience.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

Calla Lily Clinical Care is a B-Corp focused on women's health, specializing in innovative drug delivery systems. It has developed the proprietary Callavid® platform for intravaginal drug administration, aiming to enhance patient outcomes in fertility and pregnancy. The company is working towards launching the first drug-device combination product designed to prevent miscarriages and provide luteal phase support for In Vitro Fertilization (IVF). Additionally, Callavid® is capable of delivering live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic usage and the spread of antimicrobial resistance. The company also offers the Lilyvid™ device for effective medical sample collection, which facilitates advanced biomarker-based diagnostic tests for conditions such as endometriosis. The technology behind Calla Lily's devices has been recognized as a TIME Magazine Best Invention of the Year, reflecting its innovative approach to women's healthcare.

GenoME Diagnostics is a biotechnology company focused on developing innovative blood tests aimed at improving cancer detection and diagnosis. The company has created the OvaME product, which enhances the traditional CA125 blood tests, offering a more accurate and earlier detection of various cancers. By employing advanced techniques, GenoME Diagnostics aims to minimize misdiagnosis and late detection, enabling healthcare professionals to diagnose and treat patients more effectively. This commitment to developing life-saving diagnostic tools positions the company as a significant player in the field of oncology diagnostics.

DeepMirror is a developer of an artificial intelligence-based platform that enhances the drug discovery process for biopharma research and development teams. The company's technology predicts molecule properties and target affinity, allowing chemists to concentrate on the most promising drug candidates. By employing structured perception and feature fusion, DeepMirror provides robust three-dimensional analysis on devices with low power consumption, facilitating the simplification of complex data workflows. This approach not only saves researchers time but also reduces the need for extensive experimental trials, ultimately leading to the identification of more effective drugs.

Elaniti is a company focused on enhancing agricultural practices through advanced technologies in machine learning and DNA sequencing. It offers a proprietary predictive analytics service that connects soil biology to critical crop health metrics, such as yield, disease prevalence, and nutrient content. By providing insights into the complex biological makeup of soil, Elaniti empowers farmers and agronomists to make informed decisions that improve efficiency and reduce costs. The company's platform addresses the data gap in soil health and supports the transition to regenerative agriculture by optimizing the soil microbiome and fostering beneficial microbial activity. Elaniti aims to facilitate a sustainable approach to farming, contributing to environmental goals and promoting a data-driven pathway to Net-Zero agriculture.

Kelpi is a sustainable biotechnology start-up focused on bio-refining seaweed to create innovative bioplastic packaging solutions. The company develops a thin bio-plastic coating designed to replace traditional fossil fuel-based plastics used in packaging for various products, including food, beverages, cosmetics, and personal care items. By utilizing renewable feedstocks, particularly compostable seaweed, Kelpi produces marine-safe coatings for paper and cardboard packaging that have been certified recyclable. This approach allows businesses to eliminate the reliance on single-use plastics, contributing to a more sustainable and environmentally friendly packaging industry.

LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

Multus is a London-based company established in 2019 that specializes in providing tailored growth media solutions for the cultivated meat industry. By utilizing a machine learning-based approach, Multus develops completely animal-free growth media designed specifically for the efficient growth of animal cells. This innovative technology enables cultivated meat companies to scale their production affordably and sustainably, allowing them to focus on creating delicious and environmentally friendly meat alternatives. Additionally, Multus optimizes a variety of growth factor proteins produced by genetically engineered microorganisms, thereby eliminating the reliance on traditional animal serum-based media. Through its efforts, Multus aims to address the diverse needs of various animal cell types and tissues, facilitating the growth of the cultivated meat sector while significantly reducing the environmental and economic impacts associated with conventional meat production.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

Biome Bioplastics is a manufacturer specializing in the production of biodegradable and compostable bioplastics aimed at replacing conventional oil-based polymers. The company offers a diverse range of products, including high-temperature materials, non-woven fibers, flexible films, and various coating and lamination solutions. By focusing on environmentally sustainable options, Biome Bioplastics addresses the growing demand for materials that perform well both during use and at the end of their life cycle. The company employs multiple processing techniques such as injection molding, sheet extrusion, vacuum forming, and blown film to create innovative bioplastic solutions that allow clients to develop cost-effective, eco-friendly products.

Enhanced Fertility is a digital health company that uses data, artificial intelligence, and remote diagnostics to improve fertility care. It aims to increase access to fertility treatment for the 1 in 6 couples globally facing infertility, with less than 2% currently able to access needed care. The company's platform helps fertility clinics make data-driven clinical decisions, from diagnosis to treatment, to enhance live birth rates. It streamlines the patient pathway, reducing the time to treatment from three years to just 30 days through at-home testing and AI-enabled care.

Vann is a platform for people affected by cancer aiming to help millions of people globally and revolutionize cancer research and care. Vann has been backed by the Oxford University Innovation, Innovate UK, OxLEP European Regional Development Fund, and UK angel investors and is based in the UK.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Adamo Foods is a UK-based food technology company specializing in the development of plant-based whole-cut meats. Utilizing proprietary fermentation technology alongside mycelium, the company produces sustainable steak and other meat alternatives. Adamo Foods aims to provide functional meat proteins through precision fermentation, offering consumers an efficient, sustainable, and ethical food option that does not compromise on taste or experience.

aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company employs novel antibody approaches to target crucial control pathways that play a significant role in cancer cell growth, invasion, and metastasis. By utilizing anti-cancer agents, aTen Therapeutics' products have the potential to inhibit cancer cell proliferation and improve treatment outcomes for patients. Their commitment to advancing biopharmaceutical solutions reflects a goal of enhancing the quality of life for individuals affected by cancer and preventing the progression of the disease. With a management team experienced in the biopharmaceutical industry, aTen Therapeutics is well-positioned to contribute to the development of effective therapies that can significantly impact patient care.